Intersect ENT, a medical device manufacturer based in Menlo Park, California, received FDA approval for a new sinus implant. The second-generation Propel steroid-releasing implant is indicated for treating chronic sinusitis. The device is significantly smaller than its predecessor.
According to a press release by the company, the new miniature Propel device will be available at some hospitals in the United States immediately. A full launch of the product is planned for 2013. In addition, Intersect ENT plans to expand its sales force for the new Propel implant.
The first Propel mometasone furoate implant was granted FDA approval in August of last year. The device was the first in its class; no other device on the market provided controlled, localized delivery of a steroid directly to sinus tissue.
The device works propping a patient’s sinus open. This allows the device to deliver a controlled quantity of anti-inflammatory steroids directly to the lining of the sinus. In addition, the device is designed to be biodegradable. After use, the device will dissolve into the body. This can help reduce the need for follow-up surgical procedures. In addition, this also reduces the need for continual steroid dosing.